Aripiprazole: in major depressive disorder

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Major Depressive Disorder (MDD) is a prevalent mental health condition.
• Standard antidepressant therapies do not achieve adequate response in all patients.
• Atypical antipsychotics represent a therapeutic option for treatment-resistant depression.

Purpose of the Study:

• To evaluate the efficacy and tolerability of aripiprazole as adjunctive treatment for MDD.
• To assess the impact of aripiprazole on depression rating scales and patient-reported outcomes.

Main Methods:

• Two large, well-designed clinical trials were conducted.
• Adult patients with MDD and inadequate response to standard antidepressants received adjunctive aripiprazole (2-20 mg/day) or placebo for 6 weeks.
• Primary endpoint: change in Montgomery Asberg Depression Rating Scale (MADRS) total score.

Main Results:

• Adjunctive aripiprazole significantly improved mean MADRS scores compared to placebo, with benefits observed early (1-2 weeks).
• Subgroup analyses indicated consistent efficacy across different standard antidepressants, age groups, and baseline severity.
• Secondary endpoints, including Sheehan Disability Scale and Clinical Global Impression (CGI) scores, also showed significant improvement with aripiprazole.
• Higher response and remission rates were observed in the aripiprazole groups.

Conclusions:

• Aripiprazole is an effective and generally well-tolerated adjunctive treatment for adult patients with MDD experiencing an inadequate response to standard antidepressants.
• The findings support the use of aripiprazole to enhance treatment outcomes in major depressive disorder.